Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tango Therapeutics, Inc. - Common Stock (NQ:TNGX)

8.040 +0.030 (+0.37%)
Streaming Delayed Price Updated: 12:12 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Tango Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
TANGO THERAPEUTICS INC (NASDAQ:TNGX) Posts Strong Q3 Earnings Beat Amid Mixed Market Reaction
Tango Therapeutics (TNGX) reported a strong Q3, beating revenue and EPS estimates. Despite the earnings beat, the stock saw mixed market reaction. 
Via Chartmill
Topics Earnings
Earnings Scheduled For November 4, 2025
 
Via Benzinga
A Peek at Tango Therapeutics's Future Earnings
 
Via Benzinga
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares?
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares? 
Via The Motley Fool
Topics Regulatory Compliance
Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement
Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers. 
Via Benzinga
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Earnings Scheduled For May 12, 2025
 
Via Benzinga
Insights into Tango Therapeutics's Upcoming Earnings
 
Via Benzinga
Unveiling 5 Analyst Insights On Tango Therapeutics
 
Via Benzinga
The Analyst Landscape: 5 Takes On Tango Therapeutics
 
Via Benzinga
Wondering what's happening in today's pre-market session?
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Tango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer Therapy
CEO Barbara Weber said that across the 16 cancer types enrolled in the trial, the objective response rate (ORR) was 27% in patients with a median follow-up of 9.4 months. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Tango (TNGX) Q2 Revenue Drops 52%
Via The Motley Fool
Topics Intellectual Property
Analyst Scoreboard: 4 Ratings For Tango Therapeutics
 
Via Benzinga
Analyst Expectations For Tango Therapeutics's Future
 
Via Benzinga
Expert Outlook: Tango Therapeutics Through The Eyes Of 6 Analysts
 
Via Benzinga
Tango Therapeutics Inc (NASDAQ:TNGX) Reports Q2 2025 Earnings: Revenue Misses, EPS Meets Expectations Amid Clinical Progress
Tango Therapeutics (TNGX) reported Q2 2025 revenue below estimates but met EPS expectations, causing a 2.4% pre-market dip. Clinical progress in oncology trials remains a key focus. 
Via Chartmill
5 Biotech Stocks with Highly Anticipated Pending Results
Via Stocktwits
Topics Intellectual Property
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Forecasting The Future: 4 Analyst Projections For Tango Therapeutics
 
Via Benzinga
What's going on in today's session
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Which stocks are experiencing notable movement on Monday?
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity
Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now focus on its PRMT5 program and plans to update on TNG908 and TNG462 later... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.